Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID W/ COLCHICINE vs BENEMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
Probenecid: 5-8 hours (terminal half-life, prolonged in renal impairment); Colchicine: 26-31 hours (mean terminal half-life in adults, can be extended in elderly or renal/hepatic impairment).
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Probenecid: Hepatic via glucuronidation, oxidation; inhibits renal tubular secretion of many drugs. Colchicine: Hepatic via CYP3A4 and P-glycoprotein (P-gp); undergoes enterohepatic recirculation.
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Probenecid: Renal (70-80% as unchanged drug and metabolites, primarily via tubular secretion); Colchicine: Hepatic metabolism (approx. 80%) and renal excretion (10-20% unchanged). Fecal excretion of metabolites accounts for a minor fraction.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Probenecid: 85-95% bound to plasma albumin; Colchicine: 39-44% bound to albumin and alpha1-acid glycoprotein.
Approximately 85-95% bound primarily to albumin
Probenecid: 0.15-0.2 L/kg (highly confined to plasma and extracellular fluid); Colchicine: 2-5 L/kg (extensive tissue distribution, particularly in leukocytes and liver).
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
Probenecid: Oral bioavailability approximately 100% (well absorbed, but first-pass metabolism reduces systemic exposure to parent drug); Colchicine: Oral bioavailability 24-45% (subject to first-pass metabolism and transport by P-glycoprotein).
Oral: >90%
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min, reduce dose to 1 tablet once daily; for GFR > 50 m L/min, no adjustment needed.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce colchicine dose by 50% (use combination product cautiously); Child-Pugh C: contraindicated due to colchicine toxicity risk.
No specific guidelines; use with caution in severe hepatic impairment.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
Start with 1 tablet once daily; monitor renal function and colchicine toxicity due to age-related decline in GFR and increased sensitivity.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
Colchicine can cause fatal toxicity if not dosed correctly; fatalities have occurred with doses as low as 0.8 mg in patients with renal or hepatic impairment, or in combination with P-glycoprotein or CYP3A4 inhibitors.
No FDA black box warning.
Blood dyscrasias (aplastic anemia, agranulocytosis), hepatotoxicity, neuromuscular toxicity, renal impairment, drug interactions with P-gp and CYP3A4 inhibitors, use with caution in elderly and debilitated patients.
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Hypersensitivity to probenecid or colchicine, concurrent use of P-gp or strong CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine, ketoconazole), severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, pre-existing blood dyscrasias.
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Avoid high-purine foods (organ meats, shellfish, red meat, beer) as they increase uric acid and reduce drug efficacy. Alcohol, especially beer, contraindicated. Acidic foods (cranberries, citrus) may increase colchicine absorption; limit large amounts. Grapefruit may increase colchicine levels; avoid.
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in animals. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use only if clearly needed.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Colchicine: limited excretion into breast milk; M/P ratio ~0.4; low relative infant dose (~5% maternal weight-adjusted dose). Probenecid: excreted in milk but no adverse reports. Consider alternative if infant <3 months or G6PD deficiency.
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
No specific dose adjustments required; however, increased glomerular filtration rate in pregnancy may reduce probenecid efficacy; colchicine clearance unchanged. Monitor clinical response and titrate dose if needed.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
Probenecid reduces renal excretion of colchicine, increasing colchicine toxicity risk; dose adjustment required. Contraindicated in G6PD deficiency and blood dyscrasias. Monitor CBC and renal function. Use with caution in patients with peptic ulcer disease (probenecid may exacerbate). Colchicine neuromyopathy risk increases with concurrent statins or cyclosporine.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (2-3 L/day) to prevent kidney stones and help urate excretion.,Avoid alcohol, as it can increase uric acid levels and precipitate gout attacks.,Stop at first signs of infection, sore throat, or easy bruising (myelosuppression).,Report muscle pain or weakness (colchicine myopathy), especially if on statins.,Do not exceed prescribed dose; colchicine overdose can be fatal.,May cause gout flares initially; continue medication and contact provider if flares persist.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID W/ COLCHICINE vs BENEMID, answered by our medical review team.
PROBENECID W/ COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.. BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID W/ COLCHICINE and BENEMID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID W/ COLCHICINE is: 1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.. The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID W/ COLCHICINE and BENEMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID W/ COLCHICINE is classified as Category A/B. Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in . BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.